The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland-Reference-Cited by-同舟云学术

The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland

Published:2024-06-26 Issue:9 Volume:35 Page:1605-1613
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Everts-Graber Judith^ORCID,Wenger Mathias,Oser Sven,Studer Ueli,Steiner Christian,Ziswiler Hans-Rudolf,Sromek Karoline,Schmid Gernot,Gahl Brigitta,Häuselmann HansJörg,Reichenbach Stephan,Lehmann Thomas

Funder

University of Bern

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00198-024-07155-9.pdf

Reference20 articles.

1. Padhi D, Jang G, Stouch B et al (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19–26. https://doi.org/10.1002/jbmr.173

2. McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412–420. https://doi.org/10.1056/NEJMoa1305224

3. Lewiecki EM, Blicharski T, Goemaere S et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183–3193. https://doi.org/10.1210/jc.2017-02163

4. Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543. https://doi.org/10.1056/NEJMoa1607948

5. Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427. https://doi.org/10.1056/NEJMoa1708322